Drug intelligence / Profile preview

BIL-03s

Development stage: Unknown
Lead developer: Biosceptre International
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**BIL-03s** is a domain antibody (dAb) developed by Biosceptre International Ltd. targeting **non-functional P2X7 (nfP2X7)**, a biomarker associated with various solid tumors. It is designed for systemic administration to address cancer by modulating this target, with preclinical toxicology supporting a favorable safety profile, including use in compassionate access patients.[1][8][9]

Targets

nfP2X7 (Purinergic P2X7 receptor (non-functional form))

Beyond the preview

Go deeper on BIL-03s.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIL-03s.

Explore the full profile